Less than a year after coming out of stealth mode with a $65 million first-round last year, artificial intelligence specialist Insitro has already signed its first biopharma partner.
Gilead and Novo Nordisk have announced that they will collaborate on a clinical trial in nonalcoholic steatohepatitis (NASH) combining compounds from each of their pipelines, including Novo
The FDA has approved ViiV’s Dovato, a single-tablet, two drug HIV drug regimen of dolutegravir and lamivudine for treatment-naïve patients, making it the only company to have such a drug on
Gilead Sciences has filed Descovy, its successor to HIV pre-exposure prophylaxis (PrEP) therapy Truvada, in the US, spending a priority review voucher (PRV) to set up a verdict within six m